The global asthma treatment market size attained a value of 18.66 billion in 2023. The market is likely to grow further at CAGR of 4.60% during the forecast period of 2024-2032 to reach a value of nearly USD 27.97 billion by 2032, driven by the rising prevalence of asthma triggered by the poor air quality index.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Asthma is a respiratory disease in which it becomes hard for an individual to breathe due to inflammation in lungs. In this condition, the airways contract and swell, producing excess mucus and resulting in shortness of breath, cough, and wheezing. Asthma happens due to a combination of environmental and genetic factors, or either of the two. Exposure to different irritants and substances like smoke, dust, cold, stress, and certain medications, like aspirin and non-steroidal anti-inflammatory drugs, might light to asthma.
The indication and symptoms of the disease can vary from person to person. An individual may have rare asthma attacks anywhere and at any time. They can experience symptoms while working out or while running and might require immediate help. Asthma symptoms include chest pain, wheezing, shortness of breath, and trouble sleeping due to cough. All these symptoms further worsen the respiratory health.
The diagnosis of asthma depends on the severity of the disease. Based on the symptoms, the doctor may ask for various tests, like allergen tests, skin tests, and imaging tests, to determine the cause of asthma. In case of a severe condition, the doctor may ask for a spirometry test that measures the airflow through the lungs and is used to diagnose and monitor the treatment progress.
Prohibition and long-term control are the only two ways that can prevent asthma attacks to some extent. The treatment procedure for asthma patients also depends on their age and the severity of the symptoms. Long-term asthma drugs are the most relied upon asthma treatment. These drugs keep asthma under control on daily basis, which can reduce the cases of asthma attacks as well. A variety of long-term control drugs include Leukotriene modifiers, Inhaled corticosteroids, Theophylline, and Combination inhalers.
Quick-relief drugs are required for immediate and short-term relief during an asthma attack. A variety of quick-relief medicines include oral and intravenous corticosteroids, Anticholinergic agents, and short-acting beta-agonists. If a person is having an asthma attack, a quick-relief treatment can ease their symptoms immediately, providing relief. But a person should not use a quick-relief inhaler often if the long-term drugs are working correctly, as it might affect the overall treatment.
The cases of asthma treatment are constantly rising as there has been a rapid rise in airborne pollens, triggered by the rising air pollution. Deteriorating climate health and excessive use of antibiotics has significantly contributed to the rising number of asthma patients.
The Centers for Disease Control and Prevention (CDC) published instructions and urged more precautions for asthma patients during the 2019-2020 coronavirus pandemic. This was because asthma patients were more vulnerable to the fatalities of the virus. This triggered the demand for treatment medications to reduce the number of deaths, adding to the growing demand for the medications.
According to the asthma treatment market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Diagnosis Method
Market Breakup by Treatment Method
Market Breakup by Type
Market Breakup by Product Type
Market Breakup by Age
Market Breakup by Distribution Channels
Market Breakup by Treatment Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Asthma is prevalent globally because of the rise in tobacco consumption and increase in smoking. These two factors are driving the growth of the asthma treatment market. The increase in air pollution and the prevalence of indoor and outdoor allergens will further add to the number of asthma. The increase in exposure to toxic substances in the laboratory will lead to a rising populace suffering from asthma treatment.
North America is accounting highest incidence of asthma treatment worldwide. The Europe market is witnessing consistent development in the pharma industry and asthma-related therapeutics. Asia Pacific, on the other hand, is estimated to prevail highest growth rate for the estimated period. This leads to increase in global asthma treatment cost market. The awareness about different novel treatments and drugs within the communities will drive the asthma treatment market.
Numerous drugs are used to treat asthma disorders, known as asthma therapies. Asthma is triggered by indoor and outdoor factors, such as dust, pollution, and allergens. Bronchodilators and anti-inflammatory medicines, such as immunomodulators, long-acting beta-agonists (LABA), corticosteroids, methylxanthine, and leukotriene modifiers, are commonly used as medication.
The recent scientific investigation has given clinicians the devices for considerably updating the standard of care within the field of bronchial asthma. It implies decreasing steroid-related morbidity, particularly for severe asthma, and most importantly, improving the patient's lifestyle. The recent challenge is to fill the gap between the enormous potential and its execution in day-to-day clinical practice.
Depending upon the symptoms, the following drugs may be prescribed by the physicians based on the diagnosis:
Several combinations treatment drugs are used, which can be taken orally, injected, or inhaled. These medications expand the pathway into the lungs and permit airflow, improving breathing. They help in eliminating mucus from the lungs, which is easy to cough out. One of the primary reasons driving the asthma treatment market growth is the rising prevalence of asthma and other respiratory ailments and advancements in diagnostic technology.
Furthermore, rising public awareness about the availability of effective asthma drugs and treatment is driving the asthma treatment market growth. For example, inhaled corticosteroids are used to treat asthmatic individuals, whereas target-specific medications are used to treat patients with advanced diseases or chronic asthma.
Monoclonal antibodies (mAbs) that inhibit immunoglobulin E and particular cytokines are also in high demand because they are an effective way to treat chronic asthma that is not well treated by other drugs already in the market. Multiple studies have shown that monoclonal antibodies are well tolerated, improve disease control and symptoms, and minimize the requirements for large doses of inhaled corticosteroids.
The key market trends driving the growth include rising healthcare costs, significant research and development (R&D) efforts in healthcare science, and advances in healthcare infrastructure. The annual economic value of asthma was more than a hundred billion dollars, including medical expenditures.
The report gives an in-depth analysis of the key players involved in the market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the asthma treatment market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Diagnosis Method||
|Breakup by Treatment Method||
|Breakup by Type||
|Breakup by Product Type||
|Breakup by Age||
|Breakup by Distribution Channels||
|Breakup by Treatment Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Asthma Overview
3.1 Guidelines and Stages
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Asthma Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Asthma Epidemiology (2016-2031)
5.3 Europe Asthma Epidemiology (2016-2031)
5.4 Asia Pacific Asthma Epidemiology (2016-2031)
5.5 Latin America Asthma Epidemiology (2016-2031)
5.6 Middle East and Africa Asthma Epidemiology (2016-2031)
6 Global Asthma Treatment Market Overview
6.1 Global Asthma Treatment Market Historical Value (2017-2023)
6.2 Global Asthma Treatment Market Forecast Value (2024-2032)
7 Global Asthma Treatment Market Landscape
7.1 Asthma Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Asthma Treatment: Product Landscape
7.2.1 Analysis by Diagnosis method
7.2.2 Analysis by Treatment method
7.2.3 Analysis by Type
7.2.4 Analysis by Product Type
7.2.5 Analysis by Age
7.2.6 Analysis by Distribution Channel
7.2.7 Analysis by Treatment Channel
8 Asthma Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Asthma Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Asthma Treatment Market Segmentation
11.1 Global Asthma Treatment Market by Diagnosis Method
11.1.1 Market Overview
11.1.2 Physical Exam
11.1.3 Lung Test
126.96.36.199 Peak Flow
11.1.4 Imaging Test
11.1.5 Allergy Test
11.1.6 Nitric Oxide Test
11.2 Global Asthma Treatment Market by Treatment Method
11.2.1 Market Overview
11.2.2 Long Term Asthma Control Drugs
188.8.131.52 Inhaled Corticosteroids
184.108.40.206 Leukotriene Modifiers
220.127.116.11 Combination Inhalers
11.2.3 Rescue Drugs
18.104.22.168 Short-Acting Beta Agonists
22.214.171.124 Anticholinergic Agents
126.96.36.199 Oral and Intravenous Corticosteroids
11.2.4 Allergy Drugs
188.8.131.52 Allergy Shots (Immunotherapy)
184.108.40.206 Bronchial Thermoplasty
11.3 Global Asthma Treatment Market by Type
11.3.1 Market Overview
11.3.2 Mild Intermittent Asthma
11.3.3 Mild Persistent Asthma
11.3.4 Moderate Persistent Asthma
11.3.5 Severe Persistent Asthma
11.4 Global Asthma Treatment Market by Product Type
11.4.1 Market Overview
220.127.116.11 Dry Powder Inhaler
18.104.22.168 Metered Dose Inhaler
22.214.171.124 Soft Mist Inhaler
11.5 Global Asthma Treatment Market by Age
11.5.1 Market Overview
11.6 Global Asthma Treatment Market by Distribution Channels
11.6.1 Market Overview
11.6.2 Hospital Pharmacies
11.6.3 Retail Pharmacies and Drug Stores
11.6.4 Online Pharmacies
11.7 Global Asthma Treatment Market by Treatment Channel
11.7.1 Market Overview
11.8 Global Asthma Treatment Market by Region
11.8.1 Market Overview
11.8.2 North America
11.8.4 Asia Pacific
11.8.5 Latin America
11.8.6 Middle East and Africa
12 North America Asthma Treatment Market
12.1 Market Share by Country
12.2 United States of America
13 Europe Asthma Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
14 Asia Pacific Asthma Treatment Market
14.1 Market Share by Country
15 Latin America Asthma Treatment Market
15.1 Market Share by Country
16 Middle East and Africa Asthma Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.5 South Africa
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Merck and Co., Inc.
23.1.1 Company Overview
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.2 Sanofi S.A.
23.2.1 Company Overview
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.3 Astellas Pharma Inc.
23.3.1 Company Overview
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.4 Abbott Laboratories
23.4.1 Company Overview
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.5 Novartis International AG
23.5.1 Company Overview
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.6 Pfizer Inc.
23.6.1 Company Overview
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.7 Boehringer Ingelheim International GmbH
23.7.1 Company Overview
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.8 Regeneron Pharmaceuticals, Inc.
23.8.1 Company Overview
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.9 Hoffmann-La Roche Ltd.
23.9.1 Company Overview
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.10 Organon & Co.
23.10.1 Company Overview
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.11 Vectura Group Plc.
23.11.1 Company Overview
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.12 Mundipharma International Ltd.
23.12.1 Company Overview
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.13 GalxoSmithKline Plc.
23.13.1 Company Overview
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.14 Teva Pharmaceuticals Industries Ltd.
23.14.1 Company Overview
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
24 Asthma Treatment - Distribution Model (Additional Insight)
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market attained a value of USD 18.66 billion in 2023, driven by the rising prevalence of asthma.
The asthma treatment market is anticipated to grow at a CAGR of 4.60% to attain a value of USD 27.97 by 2032.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share in the market.
Factors predicted to drive the growth of the market include rise in healthcare expenditures, considerable research, development (R&D) efforts in the field of medical sciences, and advancements in healthcare infrastructure.
The condition can be diagnosed using physical exams, diagnosis method, imaging test, allergy test, and nitric oxide test, among others.
The treatment methods include long term asthma control drugs, rescue drugs, and allergy drugs, among others.
The different types of asthma include mild intermittent asthma, mild persistent asthma, moderate persistent asthma, and severe persistent asthma.
The product types include inhalers and nebulizer.
The age groups include paediatrics and adults.
The distribution channels include hospital pharmacies, retail pharmacies and drug stores, online pharmacies, among others.
The treatment channels for the condition include public and private channels.
The leading key players include Merck and Co., Inc., Sanofi S.A., Astellas Pharma Inc., Abbott Laboratories, Novartis International AG, Pfizer Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Inc., Hoffmann-La Roche Ltd., Organon & Co., Vectura Group Plc., Mundipharma International Ltd., GalxoSmithKline Plc., and Teva Pharmaceuticals Industries Ltd., among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.